International Journal of Pharmacy and Pharmaceutical Science
www.pharmacyjournal.org
Online ISSN: 2664-7230; Print ISSN: 2664-7222; Impact Factor: RJIF 5.44
Received: 10-04-2019; Accepted: 14-05-2019; Published: 23-05-2019
Volume 1; Issue 1; 2019; Page No. 41-42

Synthesis and evaluation of novel cytotoxic agents in organic chemistry

[1] AlBloushi Abdullah N
[1] Department of Chemistry, Faculty of Science, Northern Border University, 1321, Arar, Saudi Arabia

DOI: https://doi.org/10.33545/26647222.2019.v1.i1a.93

Abstract
The development of novel cytotoxic agents plays a crucial role in advancing cancer treatment. Organic chemistry has been at the forefront of synthesizing new compounds with potential therapeutic effects. This review article delves into recent advancements in the synthesis and evaluation of novel cytotoxic agents, discussing various strategies in organic synthesis, characterization techniques, and their subsequent assessment in biological systems. It also addresses the challenges and future perspectives in the design and development of these agents to enhance their efficacy and reduce side effects.

Keywords: Novel cytotoxic agents, cancer treatment, organic chemistry

Introduction
Cancer remains one of the leading causes of death globally, prompting ongoing research into more effective and safer treatment options. Cytotoxic agents, which are substances that inhibit or prevent the function of cells, leading to their death, are among the most widely used treatments for cancer. The synthesis of novel cytotoxic compounds through organic chemistry offers a pathway to discovering potent anticancer drugs with lower toxicity and greater efficacy. The exploration of unique molecular frameworks and innovative drug delivery systems in organic synthesis has opened new avenues for cancer therapy.

The Synthesis of Cytotoxic Agents
The synthesis of cytotoxic agents has evolved significantly, with researchers employing both traditional and novel organic synthesis techniques to develop compounds that can target cancer cells more selectively. The integration of combinatorial chemistry, high-throughput screening, and computer-aided drug design has greatly accelerated the discovery of new cytotoxic molecules. Additionally, the application of green chemistry principles has promoted the development of synthesis processes that are not only efficient but also environmentally benign. The targeted molecular design of cytotoxic agents has become more sophisticated with advancements in computational chemistry and molecular biology. Researchers now use structure-based drug design (SBDD) and ligand-based drug design (LBDD) techniques to create molecules that can specifically interact with cancer-specific targets such as proteins, DNA, or RNA structures involved in tumor growth and survival. This precision in design helps in identifying and synthesizing compounds that can modulate a biological pathway with high specificity, increasing the efficacy of the drug while reducing side effects. Combinatorial chemistry, coupled with high-throughput screening (HTS), has enabled the rapid synthesis and evaluation of a vast array of diverse chemical entities. This approach allows chemists to quickly generate large libraries of compounds and screen them for cytotoxic activity against a variety of cancer cell lines. The data gathered from these screens help in refining chemical libraries and focusing on those compounds that show the most promise, thereby speeding up the discovery phase and moving effective candidates into development faster. The application of green chemistry principles to the synthesis of cytotoxic agents aims to make the production of these compounds more sustainable. Techniques such as the use of non-toxic solvents, catalysts that can work under mild conditions, and procedures that minimize by-product formation are being developed and implemented. These methods not only reduce the environmental impact of drug synthesis but often enhance the overall efficiency of the process, reducing costs and waste. The integration of nanotechnology in the synthesis of cytotoxic agents offers a transformative approach to drug delivery. Nanoparticles can be engineered to carry cytotoxic drugs directly to the tumor site, enhancing the concentration of the drug in the target area while sparing healthy tissues. This targeted delivery system can be further refined by surface modification of nanoparticles with ligands that recognize and bind to receptors overexpressed on cancer cells, thereby improving the selectivity and effectiveness of the therapy. The use of biocatalysts for the synthesis of cytotoxic agents represents an emerging trend that offers several advantages, including the ability to perform highly selective transformations under mild conditions. Enzymatic processes can be used to introduce chirality or to modify complex molecules in ways that might be challenging through traditional chemical synthesis. These biotechnological approaches enhance the ability to produce novel cytotoxic compounds with high specificity and reduced toxicity.

Characterization of Novel Cytotoxic Agents
Characterization of novel cytotoxic agents is a critical phase in drug development that involves a comprehensive assessment of the chemical, physical, and biological properties of these agents to determine their suitability for further development and use in clinical settings. Initially, the process begins with confirming the chemical structure and composition of the agents. Techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and infrared spectroscopy (IR) are commonly employed. NMR spectroscopy provides detailed information about the molecular structure, including the

framework and the position of various atoms within the molecule, while mass spectrometry helps determine the molecular mass and formula, and can offer insights into the molecular structure by showing how the molecule fragments under ionization. Infrared spectroscopy identifies functional groups based on the absorption of infrared light at different wavelengths.

Following chemical analysis, physical properties such as solubility, crystallinity, melting point, and stability are assessed to predict how the compound behaves in biological systems. Solubility determines how well the compound dissolves in various solvents, which influences its bioavailability and administration route. Crystallinity and melting point provide insight into the solid-state properties of the compound, affecting its shelf life and formulation. Stability studies assess how environmental factors such as light, temperature, and pH impact the compound over time, critical for ensuring the safety and efficacy of the drug during storage and use. The biological characterization then evaluates the compound's biological activity and therapeutic potential through a variety of *in vitro* and *in vivo* tests. *In vitro* assays, including cell viability tests, apoptosis assays, and cell cycle analysis using cancer cell lines, determine the cytotoxicity of the compound, helping to identify the concentration at which the compound is effective and its mechanism of action at the cellular level. *In vivo* studies involve testing the compound in animal models to observe its effects in a living organism, including studies on how the drug is absorbed, distributed, metabolized, and excreted, its effects on the body, and its toxicity.

Biological Evaluation of Cytotoxic Compounds

The biological evaluation of cytotoxic compounds is a crucial step in the drug development process that focuses on assessing the biological activity and potential therapeutic effects of newly synthesized compounds. This process typically involves a series of tests performed *in vitro* (in test tubes or petri dishes) and *in vivo* (in living organisms), aimed at determining the efficacy and safety of these compounds as cancer treatments.

Initially, *in vitro* assays are conducted using various cancer cell lines to test the cytotoxicity of the compounds. These tests include cell viability assays, such as the MTT or XTT assays, which measure the ability of the cytotoxic compound to kill cancer cells or inhibit their growth. Apoptosis assays are also commonly performed to determine if the cell death is occurring through programmed cell death mechanisms, an ideal mode of action for anticancer drugs. Other *in vitro* tests might involve studying the effects of the compounds on the cell cycle, checking for arrest at specific phases which could indicate potential mechanisms of action.

Following promising *in vitro* results, *in vivo* testing in animal models, typically mice or rats, is conducted to study the effects of the compounds in a living system. These studies help to assess the pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted in the body) and pharmacodynamics (the biological effects of the drug on the body, including its mechanism of action) of the cytotoxic compounds. Furthermore, these studies provide critical data on the toxicity and side effects of the compounds, which are pivotal for determining the safety profile of potential drug candidates.

Conclusion

The synthesis and evaluation of novel cytotoxic agents continue to be a dynamic and vital field in organic chemistry, contributing significantly to cancer research. As our understanding of cancer biology deepens and synthetic techniques advance, the development of more effective and safer cytotoxic agents is expected to accelerate. Continued innovation and interdisciplinary collaboration will be essential for overcoming current challenges and enhancing the therapeutic arsenal against cancer.

References

1. Jiang B, Yang CG, Xiong WN, Wang J. Synthesis and cytotoxicity evaluation of novel indolylpyrimidines and indolylpyrazines as potential antitumor agents. Bioorganic & Medicinal Chemistry. 2001 May 1;9(5):1149-1154.
2. Grande F, Yamada R, Cao X, Aiello F, Garofalo A, Neamati N, *et al*. Synthesis and biological evaluation of novel hydrazide based cytotoxic agents. Expert Opinion on Investigational Drugs. 2009 May 1;18(5):555-568.
3. Hawash M, Jaradat N, Hameedi S, Mousa A. Design, synthesis and biological evaluation of novel benzodioxole derivatives as COX inhibitors and cytotoxic agents. BMC Chemistry. 2020 Dec;14:1-9.
4. Kamal A, Laxman E, Khanna GR, Reddy PS, Rehana T, Arifuddin M, e al. Design, synthesis, biological evaluation and QSAR studies of novel bisepipodophyllotoxins as cytotoxic agents. Bioorganic & Medicinal Chemistry. 2004 Aug 1;12(15):4197-4209.
5. Ghasemi S, Sharifi S, Mojarrad JS. Design, synthesis and biological evaluation of novel piperazinone derivatives as cytotoxic agents. Advanced Pharmaceutical Bulletin. 2020 Jul;10(3):423.
6. Le-Nhat-Thuy G, Van Dinh T, Pham-The H, Quang HN, Thi NN, Thi TA, *et al*. Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents. Bioorganic & Medicinal Chemistry Letters. 2018 Dec 15;28(23-24):3741-3747.
7. Routier S, Peixoto P, Mérour JY, Coudert G, Dias N, Bailly C, *et al*. Synthesis and biological evaluation of novel naphthocarbazoles as potential anticancer agents. Journal of Medicinal Chemistry. 2005 Mar 10;48(5):1401-1413.
8. Hamze A, Giraud A, Messaoudi S, Provot O, Peyrat JF, Bignon J, *et al*. Synthesis, Biological Evaluation of 1, 1-Diarylethylenes as a Novel Class of Antimitotic Agents. ChemMedChem: Chemistry Enabling Drug Discovery. 2009 Nov 2;4(11):1912-1924.
9. Figueiredo SA, Salvador JA, Cortes R, Cascante M. Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds. European Journal of Medicinal Chemistry. 2017 Oct 20;139:836-848.